



July 30, 2015

## **Biocept Announces Presentation at Next Generation Dx Summit**

### **Discussion to Feature Applications of Liquid Biopsies to Identify PDL-1 and CMET Expression in Lung Cancer**

SAN DIEGO--(BUSINESS WIRE)-- [Biocept](#), Inc. (NASDAQ: BIOC), a molecular diagnostics company commercializing and developing liquid biopsies to improve the detection and treatment of cancer, today announced that Hatim Husain, MD, of Moores Cancer Center at University of California, San Diego, and Lyle Arnold, Ph.D., Biocept's Senior Vice President and Chief Scientific Officer, will present "Applications of Liquid Biopsies to Identify PDL-1 and CMET Expression on CTCs in the Treatment of Patients with Lung Cancer" on Thursday, August 20, 2015, at the Next Generation Dx Summit being held at the Capital Hilton Hotel in Washington, D.C.

"Checkpoint inhibition with anti-PD1 and anti-PDL1 antibodies are becoming a very significant component in lung cancer therapeutics," said Dr. Husain. "The identification of a biomarker of response for these agents is timely, and investigations are needed as to whether circulating PDL1 expression on circulating tumor cells or PD1 expression on lymphocytes may be important predictive markers to complement tissue expression."

"Liquid biopsies offer a unique opportunity to profile and monitor patients with solid tumors such as lung cancer, and we appreciate the opportunity to share our development milestones and real-world experience with the scientific community attending this prestigious industry conference," said Dr. Arnold. "An entire day at this conference is dedicated to liquid biopsy, which is indicative of the level of interest it is generating among researchers, clinicians and the biopharma industry."

### **About the Next Generation Dx Summit**

The Next Generation Dx Summit, entering its seventh year, brings together more than 800 diagnostics professionals from across the world, providing comprehensive programming and valuable networking opportunities. Spanning from clinical diagnostics to business strategy, this year's expanded program encompasses predictive cancer biomarkers, companion diagnostics, infectious disease, point-of-care, pharmacy-based diagnostics, cell-free DNA, commercialization, cancer immunotherapy, and reimbursement.

### **About Biocept**

[Biocept](#), Inc. is a commercial-stage molecular diagnostics company that utilizes a proprietary technology platform and a standard blood sample to provide physicians with important prognostic and predictive information to enhance individual treatment of patients with cancer. Biocept's technology platform captures and analyzes circulating tumor DNA, both in circulating tumor cells (CTCs) and in plasma (ctDNA). Biocept currently offers testing for gastric, breast and lung cancers as well as melanoma and plans to introduce CLIA-validated tests for colorectal cancer, prostate cancer and other solid tumors in the near term.

### **Forward-Looking Statements Disclaimer Statement**

This release contains forward-looking statements that are based upon current expectations or beliefs, as well as a number of assumptions about future events. Although we believe that the expectations reflected in the forward-looking statements and the assumptions upon which they are based are reasonable, we can give no assurance that such expectations and assumptions will prove to have been correct. Forward-looking statements are generally identifiable by the use of words like "may," "will," "should," "could," "expect," "anticipate," "estimate," "believe," "intend," or "project" or the negative of these words or other variations on these words or comparable terminology. To the extent that statements in this release are not strictly historical, including without limitation statements as to the potential of our diagnostic assays to improve the detection and treatment of cancer, our impact on the field of personalized medicine and diagnostic strategies (including lung cancer therapeutics), and planned future offerings, such statements are forward-looking, and are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. The reader is cautioned not to put undue reliance on these forward-looking statements, as these statements are subject to numerous risk factors as set forth in our Securities and Exchange Commission (SEC) filings. The effects of such risks and uncertainties could cause actual results to differ materially from the forward-looking statements contained in this release. We do not plan to update any such forward-looking statements and expressly disclaim any duty to update the information contained in this press release except as required by law. Readers are advised to review our filings with the SEC, which can be accessed over the Internet at the SEC's website located at [www.sec.gov](http://www.sec.gov).

View source version on [businesswire.com](http://www.businesswire.com/news/home/20150730005340/en/): <http://www.businesswire.com/news/home/20150730005340/en/>

**Investor Contact:**

LHA

Jody Cain

310-691-7100

[jcain@lhai.com](mailto:jcain@lhai.com)

Source: Biocept, Inc.

News Provided by Acquire Media